The GI Company Expands Its Scientific Advisory Board

FRAMINGHAM, MA--(Marketwire - December 19, 2007) - The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the formal appointment of Douglas E. Peterson, DMD, Ph.D. Dr. Peterson is recognized as a thought leader in the field of oral and gastrointestinal mucosal injury that occurs secondary to high-dose cancer therapies. The GI Company's lead Phase II clinical candidate is Intestinal Trefoil Factor (ITF), an endogenous protein being developed as a drug (peptide) to treat oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and/or radiotherapy.